Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1138888

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sickle Cell Diseases: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313 on Sickle Cell Diseases, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for people with sickle cell disease; and what the per capita annual cost is of providing each of those services.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	277137
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>NHS England commissions specialised services for people living with sickle cell disease. These services are part of the specialised haemoglobinopathy services commissioned by NHS England across the country. NHS England spends over £60 million on sickle cell disease within these services annually - £60.4 million in 2017/18. Information about the services provided by individual clinical commissioning groups or other public bodies is not collected or held centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/07/2019 09:46:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 129855 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1533 label Biography information for Dame Diana Johnson

1138906

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 273480 to Question 273480 on HIV Infection: Canterbury, what steps he is taking to ensure adequate funding for PrEP after September 2020.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	277260
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>The 36 month pre-exposure prophylaxis (PrEP) Impact Trial is scheduled to continue until autumn 2020. Work is now starting to consider future commissioning for PrEP after the Trial has ended, which includes consideration of funding options.</p><p>The PrEP Impact trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. Information on why the Gate Clinic at Kent and Canterbury Hospital is not open to gay and bisexual men is not held centrally.</p><p>Following funding from NHS England to pay for extra PrEP drug and research costs and the Secretary of State’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part and the number of allocated places they can accept.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 277261 277262 question first answered 19/07/2019 09:39:20 answering member 4455 label Biography information for Seema Kennedy previous answer version 129848 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4616 label Biography information for Rosie Duffield

1138907

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genito-urinary Medicine: Canterbury
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2019 to Question 273480 on 273480, for what reason the Gate Clinic at Kent and Canterbury Hospital is not open to gay and bisexual men.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	277261
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>The 36 month pre-exposure prophylaxis (PrEP) Impact Trial is scheduled to continue until autumn 2020. Work is now starting to consider future commissioning for PrEP after the Trial has ended, which includes consideration of funding options.</p><p>The PrEP Impact trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. Information on why the Gate Clinic at Kent and Canterbury Hospital is not open to gay and bisexual men is not held centrally.</p><p>Following funding from NHS England to pay for extra PrEP drug and research costs and the Secretary of State’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part and the number of allocated places they can accept.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 277260 277262 question first answered 19/07/2019 09:39:20 answering member 4455 label Biography information for Seema Kennedy previous answer version 129846 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4616 label Biography information for Rosie Duffield

1138908

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2019 to Question 273480 on HIV Infection: Canterbury, if he will take steps to ensure that gay and bisexual men in Canterbury have access to PrEP.
	tabling member constituency	Canterbury
	tabling member printed	Rosie Duffield
	uin	277262
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>The 36 month pre-exposure prophylaxis (PrEP) Impact Trial is scheduled to continue until autumn 2020. Work is now starting to consider future commissioning for PrEP after the Trial has ended, which includes consideration of funding options.</p><p>The PrEP Impact trial is managed by the Trial Sponsor. Recruitment to places in the Trial is managed locally by participating clinics. Information on why the Gate Clinic at Kent and Canterbury Hospital is not open to gay and bisexual men is not held centrally.</p><p>Following funding from NHS England to pay for extra PrEP drug and research costs and the Secretary of State’s announcement on 30 January that the number of places on the PrEP Impact Trial would be doubled to 26,000, expansion of the Trial is now underway across the country. Participation in the Trial is on a voluntary basis and it is for research clinics and local authorities to decide whether they wish to take part and the number of allocated places they can accept.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 277260 277261 question first answered 19/07/2019 09:39:20 answering member 4455 label Biography information for Seema Kennedy previous answer version 129845 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4616 label Biography information for Rosie Duffield

1139007

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Propranolol: Somerset
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of supply of the drug Actavis Propranolol in pharmacies in (a) North East Somerset and (b) Somerset.
	tabling member constituency	North East Somerset
	tabling member printed	Mr Jacob Rees-Mogg
	uin	277188
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>The Department is assured the supply of Actavis immediate release propranolol tablets is sufficient to meet normal demand. Actavis modified release propranolol capsules are currently unavailable. However, they are expected to be back in stock by the end of July and supplies of generic propranolol capsules are currently available from an alternative manufacturer. The Department does not have information on stock holding of propranolol at a local level.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/07/2019 09:37:33 answering member 4455 label Biography information for Seema Kennedy previous answer version 129853 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4099 label Biography information for Sir Jacob Rees-Mogg

1140520

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Fish: Hygiene and Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the safety and food hygiene rules for the transport of smoked fish (a) within and (b) to the UK is governed by (i) UK or (ii) EU regulations.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	279407
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The longstanding rules governing the transport of food of animal origin, including smoked fish are provided by European Union food safety and hygiene regulations which apply directly to the United Kingdom. This legislation lays down effective and proportionate food safety and hygiene controls throughout the food chain, from primary production to sale or supply to the food consumer. In England, The Food Safety and Hygiene (England) Regulations 2013 provides for the enforcement of certain provisions of EU food safety hygiene legislation. It also provides national law for certain elements including temperature control in retail establishments. Parallel legislation applies in Scotland, Wales and Northern Ireland.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:42:59 answering member 4455 label Biography information for Seema Kennedy previous answer version 131082 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1140557

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Kawasaki Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of (a) the potential cost savings of improving early identification and treatment of Kawasaki disease and (b) the potential consequent reduction in demand for long-term specialist care for children with that disease.
	tabling member constituency	Cardiff West
	tabling member printed	Kevin Brennan
	uin	279381
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The requested information is not available and therefore no such estimate has been made.</p><p>NHS Improvement has previously published a Patient Safety Alert for the attention of providers of National Health Service-funded care to emphasise the high risk and atypical presentation of coronary artery aneurysms, coronary thrombosis and myocardial ischaemia or infarction in patients with Kawasaki disease, and to highlight the importance of specialist advice.</p><p>Guidance is also available from the National Institute for Health and Care Excellence (NICE) on the assessment and initial management of fever in children under five, and this guidance includes recommendations on recognising the symptoms of Kawasaki disease.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:40:10 answering member 4455 label Biography information for Seema Kennedy previous answer version 131089 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1400 label Biography information for Kevin Brennan

1140558

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Kawasaki Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what support his Department is providing to (a) enable early treatment and (b) increase awareness amongst healthcare providers of Kawasaki disease .
	tabling member constituency	Cardiff West
	tabling member printed	Kevin Brennan
	uin	279382
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>NHS Improvement has previously published a Patient Safety Alert for the attention of providers of National Health Service-funded care to emphasise the high risk and atypical presentation of coronary artery aneurysms, coronary thrombosis and myocardial ischaemia or infarction in patients with Kawasaki disease, and to highlight the importance of specialist advice.</p><p>Guidance is also available from the National Institute for Health and Care Excellence (NICE) on the assessment and initial management of fever in children under five, and this guidance includes recommendations on recognising the symptoms of Kawasaki disease.</p><p>NICE’s clinical guidelines help healthcare professionals deliver the best possible care based on the best available evidence; the guidelines are not mandatory, although health and care commissioners are expected to take them fully into account.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:37:42 answering member 4455 label Biography information for Seema Kennedy previous answer version 131090 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1400 label Biography information for Kevin Brennan

1140559

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Kawasaki Disease: Medical Records
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a patient registry on Kawasaki disease.
	tabling member constituency	Cardiff West
	tabling member printed	Kevin Brennan
	uin	279383
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>No such assessment has been made.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:41:26 answering member 4455 label Biography information for Seema Kennedy previous answer version 131091 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1400 label Biography information for Kevin Brennan

1140582

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279389
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb